Demcizumab

From Wikipedia, the free encyclopedia
Demcizumab ?
Monoclonal antibody
Source Humanized (from mouse)
Target DLL4
Clinical data
Legal status ?
Identifiers
CAS number 1243262-17-0
ATC code None
Chemical data
Formula C6444H10004N1700O2028S52 
Mol. mass 145.3 kDa

Demcizumab is a humanized monoclonal antibody designed for the treatment of cancer.[1]

This drug was developed by OncoMed Pharmaceuticals.

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Demcizumab, American Medical Association.
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
Bone ("-os-", "-s(o)-")
Human ("-osu-")
Humanized ("-sozu-")
Musculoskeletal ("-mul-")
Human ("-mulu-")
Circulatory ("-c(i[r])-")
Human ("-ciru-")
Mouse ("-ciro-")
Chimeric ("-cixi-")
Humanized ("-cizu-")
Neurologic ("-ne(u)(r)-")
Human ("-neru-")
Humanized ("-nezu-"/"-neuzu-")
Angiogenesis inhibitor ("-anibi-")
Humanized ("-anibizu-")



This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.